Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NETWORK × Breast Cancer Invasive Nos × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 70 Lung Neoplasms 60 Breast Neoplasms 56 Lymphoma 51 Ovarian Neoplasms 44 Sarcoma 42 Leukemia 37 Prostatic Neoplasms 36 Multiple Myeloma 36 Central Nervous System Neoplasms 33 Head and Neck Neoplasms 32 Colorectal Neoplasms 30 Squamous Cell Carcinoma of Head and Neck 29 Rectal Neoplasms 28 Melanoma 28 Carcinoma, Ovarian Epithelial 28 Neoplasm Metastasis 26 Lymphoma, Large B-Cell, Diffuse 24 Urinary Bladder Neoplasms 23 Precursor Cell Lymphoblastic Leukemia-Lymphoma 23 Leukemia, Lymphocytic, Chronic, B-Cell 23 Brain Neoplasms 23 Uterine Cervical Neoplasms 22 Endometrial Neoplasms 22 Adenocarcinoma of Lung 21 Leukemia, Myeloid, Acute 20 Glioblastoma 20 Fallopian Tube Neoplasms 20 Gliosarcoma 17 Lymphoma, Mantle-Cell 16

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Triptorelin Pamoate 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02005887 2019-05-29

TREND

ETOP IBCSG Partners Foundation

Phase 2 Completed

51 enrolled 10 charts

Breast Cancer Invasive Nos

Data powered by HemOnc (CC BY 4.0) Colophon ⚡